Financial Performance - The company's operating revenue for Q1 2025 was CNY 348,152,134.38, representing a 12.60% increase compared to CNY 309,185,113.48 in the same period last year[4] - Net profit attributable to shareholders was CNY 58,923,751.17, up 17.25% from CNY 50,255,959.75 year-over-year[4] - The net profit after deducting non-recurring gains and losses was CNY 56,645,532.50, reflecting a 20.49% increase from CNY 47,011,106.82 in the previous year[4] - Basic and diluted earnings per share were both CNY 0.20, an increase of 17.65% from CNY 0.17 in the same period last year[4] - Total operating revenue for Q1 2025 reached ¥348,152,134.38, an increase of 12.6% compared to ¥309,185,113.48 in Q1 2024[19] - Net profit for Q1 2025 was ¥60,580,787.50, representing a 15.4% increase from ¥52,550,428.60 in Q1 2024[19] - The company reported a total comprehensive income of ¥60,945,099.59 for Q1 2025, compared to ¥52,550,428.60 in Q1 2024[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 60.96%, amounting to CNY 14,992,693.07, primarily due to increased cash payments for goods and services[8] - Cash flow from operating activities generated a net amount of ¥14,992,693.07, down from ¥38,407,488.30 in the same period last year[23] - Cash flow from investing activities showed a net inflow of ¥32,688,994.48, a significant improvement from a net outflow of ¥140,189,372.53 in Q1 2024[24] - The company's total investment cash outflow for Q1 2025 was ¥229,145,284.35, compared to ¥284,844,630.59 in Q1 2024[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,833,924,311.61, a slight decrease of 0.24% from CNY 2,840,682,536.11 at the end of the previous year[5] - As of March 31, 2025, the total current assets amounted to RMB 893,373,560.61, a slight increase from RMB 886,060,586.29 as of December 31, 2024, reflecting a growth of approximately 0.15%[13] - The total liabilities decreased to RMB 869,904,579.74 from RMB 937,607,903.83, indicating a reduction of approximately 7.25%[15] - The company's non-current assets totaled RMB 1,940,550,751.00, down from RMB 1,954,621,949.82, reflecting a decrease of approximately 0.72%[14] Shareholder Equity - Shareholders' equity attributable to shareholders increased by 3.14% to CNY 1,944,245,569.60 from CNY 1,884,975,721.94[5] - The company's total equity increased to RMB 1,964,019,731.87 from RMB 1,903,074,632.28, indicating a growth of about 3.03%[15] Other Financial Metrics - The weighted average return on equity rose to 3.08%, an increase of 0.35 percentage points from 2.73%[4] - The company's retained earnings increased to RMB 887,451,887.55 from RMB 828,528,136.38, showing a growth of about 7.39%[15] - The inventory increased to RMB 173,481,526.95 from RMB 168,612,539.09, reflecting a growth of approximately 2.16%[14] - The short-term borrowings decreased to RMB 90,059,124.95 from RMB 110,074,486.06, a decline of approximately 18.24%[14] - The company's long-term borrowings increased to RMB 360,834,989.32 from RMB 327,740,062.99, representing a growth of about 10.09%[15] - The company's research and development expenses for Q1 2025 were ¥21,233,816.26, slightly up from ¥20,475,295.90 in Q1 2024[19]
维力医疗(603309) - 2025 Q1 - 季度财报